Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Subjects will be treated with vorinostat administered orally with daily dosing for 14 days of a 21-day treatment cycle in combination with niacinamide administered orally for 14 days in 21-day treatment cycle and etoposide administered intravenously on days 8,9 and 10 of a 21-day treatment cycle. Etoposide dose will be escalated until maximum tolerated dose (MTD) is determined.

Inclusion criteria

• Histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's Disease (WHO criteria), for which they are unwilling or unable to undergo an autologous stem cell transplant
• Must have received first line chemotherapy. No upper limit to number of prior therapies
• Evaluable Disease
• Age >18 years
• Eastern Cooperative Oncology Group (ECOG) performance status <2
• Life expectancy of greater than 3 months
• Patients must have adequate organ and marrow function
• Adequate Contraception
• Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

• Prior Therapy

• Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone during the 7 days prior to the start of the study drugs
• No monoclonal antibody within 3 months unless evidence of progression
• Patients may not be receiving any other investigational agents
• Patients with known central nervous system metastases, including lymphomatous meningitis
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, niacinamide or etoposide
• Uncontrolled intercurrent illness
• Pregnant women
• Nursing women
• Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 3 years
• Patient is known to be Human Immunodeficiency Virus (HIV)-positive
• Active Hepatitis A, Hepatitis B, or Hepatitis C infection
• Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs